The Pemphigus drugs in development market research report provides comprehensive information on the therapeutics under development for Pemphigus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pemphigus. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pemphigus - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pemphigus and features dormant and discontinued products.

GlobalData tracks 18 drugs in development for Pemphigus by 18 companies/universities/institutes. The top development phase for Pemphigus is preclinical with ten drugs in that stage. The Pemphigus pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pemphigus pipeline products market are: Cabaletta Bio, Avotres and ImmunoWork.

The key targets in the Pemphigus pipeline products market include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC, Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN).

The key mechanisms of action in the Pemphigus pipeline product include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC Inhibitor with three drugs in Phase III. The Pemphigus pipeline products include four routes of administration with the top ROA being Intravenous and seven key molecule types in the Pemphigus pipeline products market including Monoclonal Antibody, and Small Molecule.

Pemphigus overview

Pemphigus is is an autoimmune disease that causes blistering of the skin and the the mucous membranes inside of the mouth, nose, throat, eyes, and genitals. It is characterized by loss of normal cell-cell adhesion (acantholysis) and by the presence of pathogenic (predominantly IgG) autoantibodies reacting against epithelial adhesion molecules called desmogleins, proteins that bind skin cells to one another. When these bonds are disrupted, skin becomes fragile, and fluid can collect between its layers, forming blisters.

For a complete picture of Pemphigus’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.